Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0XT0W
|
|||
| Former ID |
DIB014926
|
|||
| Drug Name |
Debio 1347
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 2 | [1] | |
| Breast cancer [ICD-11: 2C60-2C65] | Phase 1/2 | [2] | ||
| Company |
Debiopharm
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H16N6O
|
|||
| Canonical SMILES |
CC1=NC2=C(N1)C=C(C=C2)N3C(=C(C=N3)C(=O)C4=CC5=CC=CC=C5N4)N
|
|||
| InChI |
1S/C20H16N6O/c1-11-23-16-7-6-13(9-17(16)24-11)26-20(21)14(10-22-26)19(27)18-8-12-4-2-3-5-15(12)25-18/h2-10,25H,21H2,1H3,(H,23,24)
|
|||
| InChIKey |
BEMNJULZEQTDJY-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1265229-25-1
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03834220) Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol Cancer Ther. 2014 Nov;13(11):2547-58. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.